Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer.

[1]  R. Gray,et al.  Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  D. Heitjan,et al.  Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. , 1995, The Journal of clinical endocrinology and metabolism.

[3]  C. Murdoch,et al.  Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. , 2013, Seminars in cancer biology.

[4]  T. Oyama,et al.  Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[6]  G. Mills,et al.  An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2 , 2015, Clinical Cancer Research.

[7]  I. Wistuba,et al.  Aromatase expression predicts survival in women with early-stage non small cell lung cancer. , 2007, Cancer research.

[8]  R. Johnson,et al.  A role for VEGF as a negative regulator of pericyte function and vessel maturation. , 2008, Nature.

[9]  Hideki Kawai,et al.  Estrogen Receptor α and β are Prognostic Factors in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[10]  H. Schnaper,et al.  Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. , 1995, Circulation.

[11]  T. Larson,et al.  Phase II Study of Biweekly Carboplatin, Gemcitabine, and Bevacizumab as First-line Treatment in Patients with Stage IIIB/IV NSCLC , 2014, American journal of clinical oncology.

[12]  Markus Kipp,et al.  Combined Application of 17β-Estradiol and Progesterone Enhance Vascular Endothelial Growth Factor and Surfactant Protein Expression in Cultured Embryonic Lung Cells of Mice , 2009, International journal of pediatrics.

[13]  D. Hanahan,et al.  Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. , 2011, Blood.

[14]  Gordon C Jayson,et al.  Antiangiogenic therapy in oncology: current status and future directions , 2016, The Lancet.

[15]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[16]  Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases , 2019, Scientific Reports.

[17]  R. Herbst,et al.  Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. , 2011, The Journal of clinical investigation.

[18]  J. Luketich,et al.  Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. , 2002, Cancer research.

[19]  E. Baldini,et al.  Women and lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  R. Kishore,et al.  17Beta-estradiol mobilizes bone marrow-derived endothelial progenitor cells to tumors. , 2008, Cancer research.

[21]  A. Miller,et al.  Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. , 1993, American journal of epidemiology.

[22]  M. Fishbein,et al.  Aromatase inhibitors in human lung cancer therapy. , 2005, Cancer research.

[23]  J. Siegfried,et al.  Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. , 2005, Cancer research.

[24]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[25]  M. J. Jarzynka,et al.  Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. , 2006, International journal of oncology.

[26]  D. Hanahan,et al.  Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting , 2008, PLoS medicine.

[27]  M. Fishbein,et al.  Estrogen receptor signaling pathways in human non-small cell lung cancer , 2007, Steroids.

[28]  L. Holmberg,et al.  Lung cancer incidence in never smokers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  O. Miettinen,et al.  Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. , 2006, JAMA.

[30]  Xianglin L. Du,et al.  Menopausal Hormone Therapy and Lung Cancer-Specific Mortality Following Diagnosis: The California Teachers Study , 2014, PloS one.

[31]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[32]  A. Potti,et al.  Hormone replacement therapy is associated with decreased survival in women with lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Zhuo Wang,et al.  Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: a systems biology perspective , 2019, Journal of Translational Medicine.

[34]  L. Bubendorf,et al.  Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). , 2012, Lung cancer.

[35]  O. Arrieta,et al.  Influence of estrogen in non-small cell lung cancer and its clinical implications. , 2018, Journal of thoracic disease.

[36]  Steven Song,et al.  The role of pericytes in blood-vessel formation and maintenance. , 2005, Neuro-oncology.

[37]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[38]  A R Dunn,et al.  Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. , 1994, Blood.

[39]  G. Blumenschein,et al.  Angiogenesis Inhibitors for Lung Cancer: Clinical Developments and Future Directions , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[40]  J. Dering,et al.  Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[42]  J. Manson,et al.  Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. , 2010, Journal of the National Cancer Institute.

[43]  J. Minna,et al.  Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells , 2010, Oncogene.

[44]  J. Siegfried,et al.  Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  Patricia A. Young,et al.  Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. , 2018, Lung cancer.

[46]  R. DuBois,et al.  CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer. , 2017, Cancer research.

[47]  B. Li,et al.  Gender Differences in Low-Molecular-Mass-Induced Acute Lung Inflammation in Mice , 2021, International journal of molecular sciences.

[48]  Y. Meng,et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.

[49]  T. Bruno,et al.  Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications , 2020, Frontiers in Oncology.

[50]  I. Wistuba,et al.  Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation , 2009, Clinical Cancer Research.

[51]  L. Striker,et al.  Female gender, estrogen loss, and Sub-RPE deposit formation in aged mice. , 2003, Investigative ophthalmology & visual science.

[52]  Kathleen A Cronin,et al.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics , 2018, Cancer.

[53]  Michael C. Schmid,et al.  Myeloid cell trafficking and tumor angiogenesis. , 2007, Cancer letters.

[54]  L. Ellis,et al.  Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy , 2008, Clinical Cancer Research.

[55]  W. McGuire,et al.  Induction of the estrogen-regulated "24K" protein by heat shock. , 1989, Cancer research.

[56]  J. Siegfried,et al.  Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco‐Induced Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[57]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[58]  U. Landegren,et al.  Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. , 2003, Genes & development.